Your session is about to expire
← Back to Search
Study Summary
This trial will study a new MS drug in children to see if it is safe and effective. Part 1 will assess how the drug works in the body, and Part 2 will evaluate long-term safety and effectiveness.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2013 Phase 3 trial • 1516 Patients • NCT00906399Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I could not tolerate BIIB017 in an earlier part of the study.My condition has been getting worse continuously for at least 3 months.My disability score is between 0.0 and 5.5.My condition has worsened or shown activity recently.I have had an MS flare-up within the last 30 days or haven't recovered from a recent one.I have been treated with PEGylated human IFN β-1a before.I have been diagnosed with relapsing-remitting MS.
- Group 1: BIIB017 (peginterferon beta-1a)
- Group 2: Avonex
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are the requirements for this trial limiting it to a specific age group?
"This particular research study is focused on children aged 10-18."
Am I an eligible candidate for this research?
"The current clinical trial has a set of inclusion criteria that requires potential participants to have multiple sclerosis, be in an acute relapsing state, and be between the ages of 10 and 18. Up to 142 patients will be accepted into the trial."
Are there any risks associated with BIIB017 (peginterferon beta-1a)?
"BIIB017 (peginterferon beta-1a) has been studied in Phase 3 trials, meaning that there is both safety and efficacy data available. Our team rates it as a 3 on our safety scale."
What purpose does BIIB017 (peginterferon beta-1a) serve most often?
"BIIB017 is most often used as part of a parenteral drug administration therapy regimen. It has also shown efficacy in treating multiple sclerosis, carcinoma in situ, and parenteral drug administration."
What is the efficacy of BIIB017 in other medical research?
"25 studies are currently underway to study the efficacy of BIIB017 (peginterferon beta-1a), 13 of which are in Phase 3. The trials for BIIB017 are largely based in Milwaukee, Wisconsin, but there are 1,555 locations across the globe conducting these experiments."
Share this study with friends
Copy Link
Messenger